tsk as usually you are poo pooing without reading. You'd be funny if you weren't so condescending. The attitude of real science indeed.
Hello, I am talking about anticoagulation, as Sam has already realized. Remember that the next time you call him a Neanderthal. As for your study, don't have time. It may say this but given your track record I am willing to bet it says more than that too. In any event there are other studies, peer-reviewed, my friend. See the archives; posted them this summer. Ther aren't a lot -- there are problems with establishing a standard does as I have already mentioned. Dana On 12/4/05, Larry C. Lyons <[EMAIL PROTECTED]> wrote: > > I think that this Cocheran based meta analysis summarizes the attitude > of real science, there is no real effect for ginko beyond a placebo. > > http://www.antiwrap.com/?789 > > Ginkgo biloba Compared with Cholinesterase Inhibitors in the Treatment > of Dementia: A Review Based on Meta-Analyses by the Cochrane > Collaboration > A. Kurza, B. Van Baelenb > > aDepartment of Psychiatry and Psychotherapy, Technical University > Munich, Munich, Germany; > bMedisearch International, Mechelen, Belgium > > Dementia and Geriatric Cognitive Disorders 2004;18:217-226 (DOI: > 10.1159/000079388) > > Abstract > > Data were derived from the Cochrane Collaboration meta-analyses of the > efficacies of ginkgo, donepezil, rivastigmine and galantamine on > changes in cognitive function in patients with dementia and, where > necessary, were transformed to standardized mean differences. The > proportion of patients discontinuing trials was used as a proxy > measure of tolerability. Outcomes were assessed after 6 months of > treatment. Trial data for cholinesterase inhibitors were more > consistent than those for ginkgo, particularly regarding patient > populations and outcome measures. Significant benefits on cognition > vs. placebo were seen with donepezil, 5 and 10 mg, rivastigmine, 6-12 > mg, and galantamine, 16 and 24 mg. Significant benefit vs. placebo > with ginkgo was seen only when all doses were pooled. Similar > proportions of patients discontinued treatment with ginkgo and > placebo. Cholinesterase inhibitors were also well tolerated, although > a significantly greater proportion of patients receiving active > treatment discontinued vs. placebo with some doses. An evidence-based > medicine approach, taking into account the quality of clinical trials, > is essential when assessing the safety and efficacy of medications. > -- > > ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~| Discover CFTicket - The leading ColdFusion Help Desk and Trouble Ticket application http://www.houseoffusion.com/banners/view.cfm?bannerid=48 Message: http://www.houseoffusion.com/lists.cfm/link=i:5:185680 Archives: http://www.houseoffusion.com/cf_lists/threads.cfm/5 Subscription: http://www.houseoffusion.com/lists.cfm/link=s:5 Unsubscribe: http://www.houseoffusion.com/cf_lists/unsubscribe.cfm?user=11502.10531.5 Donations & Support: http://www.houseoffusion.com/tiny.cfm/54
